• image

    the Phase 3 trial DIAGNODE-3

    and other ongoing trials

  • image

    Developing precision therapies

    for type 1 diabetes

  • image

    Intralymphatic immunotherapy

    with Diamyd®

Company Presentation

 February 23, 2024

The recent U.S. market research has yielded promising insights, demonstrating a strong willingness among healthcare practitioners and payers to consider prescribing Diamyd® for type 1 diabetes.

image Ulf Hannelius
President and CEO, Diamyd Medical AB
CEO Comments, Quarterly Report 1 23/24


 Dates for financial information and other events
March 6 − March 9, 2024
ATTD 2024, Florence, Italy
March 6, 2024
Life Science-dagen 2024
Wallenberg Conference Centre, Gothenburg. Company presentation by CEO Ulf Hannelius at 11:15 CET.
March 27, 2024
Quarterly Report II
Quarterly Report 2 2023/2024
May 12 − May 14, 2024
Bio€quity Europe 2024
June 21 − June 24, 2024
ADA 84th Scientific Sessions
June 26, 2024
Quarterly Report III
Quarterly Report 3 2023/2024
October 9, 2024
Year-End Report
Year-End Report 2023/2024

The Story of Diamyd Medical

The company founder Anders Essen-Möller reveals the story behind the company's founding and his mission to stop type 1 diabetes in its tracks. The film also features board member Karin Hehenberger, shedding light on the patient’s perspective, and board member Dr. Mark Atkinson speaking of the importance of the enzyme GAD in type 1 diabetes.

“ If it was not for the hundreds of clinical sites and their personnel, investigators, patients, investors, not to mention the fantastic entrepreneurial, yet diligent, Diamyd team - this current transformational precision therapy for autoimmune diabetes based on genetics, should probably still remain undiscovered.
How can I thank you all ? "

- Anders Essen-Möller, Chairman of the Board
A new facility for manufacturing of biological products is being set up in Umeå, the Capital of Västerbotten County in Sweden. The primary purpose is the manufacture of recombinant GAD65, the active pharmaceutical ingredient in the investigational medicine Diamyd®, an antigen-specific immunotherapy currently in late-stage clinical development.

Diamyd Medical has chosen Cytiva’s FlexFactory, a configurable single-use bioprocess platform for the manufacturing process that is based on a baculovirus-insect cell expression system.
Read More


Diamyd Medical develops therapies for type 1 diabetes
The share is listed on Nasdaq First North Growth Market (ticker: DMYD B)

Read More

Order GAD for preclinical research